drugset / Trial / NCT04046107
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
Phase 1/2
Withdrawn
National Institute of Allergy and Infectious Diseases (NIAID)
Regeneron Pharmaceuticals · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and immunotherapeutic activity of cemiplimab in participants with hepatitis B virus (HBV) on suppressive antiviral therapy.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Cemiplimab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Cemiplimab | Monoclonal antibody | 3 mg/kg | Intravenous |